Innogen Pharmaceuticals Gets Boost for Global Expansion with GMP Certification

Innogen Pharmaceuticals has achieved a significant milestone in its global expansion efforts. The company's manufacturing facility for Efsubaglutide alfa, a treatment for type 2 diabetes and obesity, has received certification from the Brazilian National Health Surveillance Agency (ANVISA) under the Pharmaceutical Inspection Co-operation Scheme (PIC/S) Good Manufacturing Practice (GMP) standards.

This certification will accelerate the registration and commercial launch of Efsubaglutide alfa in Brazil and other emerging markets that recognize the PIC/S GMP framework, including Hong Kong, Southeast Asia, and Latin America. According to IQVIA reports, Brazil's pharmaceutical market reached US$35.6 billion in 2023, making it a key focus for Innogen's overseas commercialization strategy.

Professor Wang Qinghua, Founder, Chairman, and CEO of Innogen Pharmaceuticals, commented on the achievement: 'This recognition under the PIC/S GMP framework marks a significant milestone in the development of our global quality systems.'